Inspire Will Use Allergy Expertise To Develop Phase III Antihistamine Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Inspire acquires the rights to FAES’ bilastine for the treatment or prevention of allergic rhinitis.